Distribution of MED12 Mutations in Fibroadenomas and Phyllodes Tumors of the Breast-Implications for Tumor Biology and Pathological Diagnosis

Genes Chromosomes and Cancer

Volumn 54, Issue 7, 2015, Pages 444-452

  Pfarr, Nicole ^a   Kriegsmann, Mark ^a   Sinn, Peter ^a   Klauschen, Frederick ^b   Endris, Volker ^a   Herpel, Esther ^a,c   Muckenhuber, Alexander ^a   Jesinghaus, Moritz ^a   Klosterhalfen, Bernd ^d   Penzel, Roland ^a   Lennerz, Jochen K ^e   Weichert, Wilko ^a,c   Stenzinger, Albrecht ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Emergency Medicine and Pain Therapy   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; DNA; SERINE; MED12 PROTEIN, HUMAN; MEDIATOR COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; BINDING SITE; BREAST FIBROADENOMA; CANCER DIAGNOSIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; EXON; GENE; HUMAN; HUMAN TISSUE; INTRON; MED12 GENE; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; VERY ELDERLY; YOUNG ADULT; BREAST NEOPLASMS; COHORT ANALYSIS; FEMALE; FIBROADENOMA; GENETICS; MUTATION; PATHOLOGY; PHYLLODES TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FIBROADENOMA; HUMANS; MEDIATOR COMPLEX; MIDDLE AGED; MUTATION; PHYLLODES TUMOR; YOUNG ADULT;

EID: 84929605607     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22256     Document Type: Article

References (36)

1. Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, Drumea K, Lagneau E, Kadish SP, Scandolaro L, Azria D, Ozsahin M. 2008. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 70:492-500.
2. Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, Mittal K, Kong B, Kurita T, Wei JJ. 2014. MED12 and HMGA2 mutations: Two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol 27:1144-1153.
3. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD, Jr., Rados MS, Schuyler PA. 1994. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331:10-15.
4. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ. 2014. COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805-D811.
5. Franco N, Picard SF, Mege F, Arnould L, Lizard-Nacol S. 2001. Absence of genetic abnormalities in fibroadenomas of the breast determined at p53 gene mutations and microsatellite alterations. Cancer Res 61:7955-7558.
6. Geisler DP, Boyle MJ, Malnar KF, McGee JM, Nolen MC, Fortner SM, Broughan TA. 2000. Phyllodes tumors of the breast: A review of 32 cases. Am Surg 66:360-366.
7. Gillmor CS, Silva-Ortega CO, Willmann MR, Buendía-Monreal M, Poethig RS. 2014. The Arabidopsis Mediator CDK8 module genes CCT (MED12) and GCT (MED13) are global regulators of developmental phase transitions. Development 141:4580-4589.
8. Giri D. 2009. Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med 133:713-721.
9. Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LF, Bernards R. 2012. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151:937-950.
10. Je EM, Kim MR, Min KO, Yoo NJ, Lee SH. 2012. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 131:E1044-E1047.
11. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ; Phyllodes Tumour Consortium. 2008. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 214:533-544.
12. Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari LM, Mehine M, Schrewe H, Nevanlinna H, Levine RL, Hokland P, Böhling T, Mecklin JP, Bützow R, Aaltonen LA, Vahteristo P. 2012. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer 107:1761-1765.
13. Karim RZ, O'Toole SA, Scolyer RA, Cooper CL, Chan B, Selinger C, Yu B, Carmalt H, Mak C, Tse GM, Tan PH, Putti TC, Lee CS. 2013. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. J Clin Pathol 66:496-505.
14. Kim S, Xu X, Hecht A, Boyer TG. 2006. Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem 281:14066-14075.
15. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. 2012. WHO classification of Tumours of the Breast, 4th ed. IARC, Lyon.
16. Lee AH, Hodi Z, Ellis IO, Elston CW. 2007. Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. Histopathology 51:336-344.
17. Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, Cutcutache I, Poore G, Tay ST, Ooi WS, Tan VK, Hartman M, Ong KW, Tan BK, Rozen SG, Tan PH, Tan P, Teh BT. 2014. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 46:877-880.
18. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA. 2011. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334:252-255.
19. Mäkinen N, Vahteristo P, Kämpjärvi K, Arola J, Bützow R, Aaltonen LA. 2013. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet 21:1300-1303.
20. Markowski DN, Huhle S, Nimzyk R, Stenman G, Löning T, Bullerdiek J. 2013. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors. Genes Chromosomes Cancer 52:297-304.
21. Matsubara A, Sekine S, Yoshida M, Yoshida A, Taniguchi H, Kushima R, Tsuda H, Kanai Y. 2013. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology 62:657-661.
22. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. 2012. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 7:e33251.
23. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ, Ballard D, Conway K, Liu ET . 1995. p53 mutations in benign breast tissue. J Clin Oncol 13:2293-2300.
24. Mituś J, Reinfuss M, Mituś JW, Jakubowicz J, Blecharz P, Wysocki WM, Skotnicki P. 2014. Malignant phyllodes tumor of the breast: Treatment and prognosis. Breast J 20:639-644.
25. Ravegnini G, Mariño-Enriquez A, Slater J, Wang Y, Zhu M, Nucci MR, George S, Angelini S, Raut CP, Fletcher JA. 2013. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol 26:743-749.
26. Reinfuss M, Mituś J, Duda K, Stelmach A, Ryś J, Smolak K. 1996. The treatment and prognosis of patients with phyllodes tumor of the breast: An analysis of 170 cases. Cancer 77:910-916.
27. Rocha PP, Scholze M, Bleiss W, Schrewe H. 2010. Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development 137:2723-2731.
28. Schwetye KE, Pfeifer JD, Duncavage EJ. 2014. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol 45:65-70.
29. Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, Sangalli C, Catania C, Toffalorio F, Noberasco C, Delmonte A, Luini A, Veronesi P, Colleoni M, Viale G, Zurrida S, Goldhirsch A, Veronesi U, De Pas T. 2013. Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 88:427-436.
30. Stenzinger A, Pfarr N, Endris V, Penzel R, Jansen L, Wolf T, Herpel E, Warth A, Klauschen F, Kloor M, Roth W, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M, Weichert W. 2014. Mutations in POLE and survival of colorectal cancer patients-Link to disease stage and treatment. Cancer Med 3:1527-1538.
31. Taatjes DJ. 2010. The human Mediator complex: A versatile, genome-wide regulator of transcription. Trends Biochem Sci 35:315-322.
32. Tan PH, Ellis IO. 2013. Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: Updates from the WHO Classification of Tumours of the Breast 2012. J Clin Pathol 66:465-470.
33. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. 2010. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn 12:697-704.
34. Wu SY, de Borsetti NH, Bain EJ, Bulow CR, Gamse JT. 2014. Mediator subunit 12 coordinates intrinsic and extrinsic control of epithalamic development. Dev Biol 385:13-22.
35. Yang X, Kandil D, Cosar EF, Khan A. 2014. Fibroepithelial tumors of the breast: Pathologic and immunohistochemical features and molecular mechanisms. Arch Pathol Lab Med 138:25-36.
36. Zhou H, Kim S, Ishii S, Boyer TG. 2006. Mediator modulates Gli3-dependent Sonic hedgehog signaling. Mol Cell Biol 26:8667-8682.